Regeneron Pharmaceuticals, Inc. (REGN)

NMS – Real Time Price. Currency in USD

737.71

-19.02 (-2.51%)

At close: Mar 27, 2026, 4:00 PM EDT

740.00

+2.29 (0.31%)

After-hours: Mar 27, 2026, 5:57 PM EDT

27.03.2026

Is Regeneron a Multimillionaire-Maker Stock?

The company is slowly recovering from recent headwinds. It could perform well through the next five to 10 years.

25.03.2026

REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?

Regeneron's rally reflects biotech momentum as pipeline wins and Dupixent growth offset Eylea erosion amid intensifying competition.

24.03.2026

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo

24.03.2026

Press Release: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

12.03.2026

In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making

Regeneron's shares are positioned to rise, thanks to the performance of its pipeline. Its top-selling drug, Dupixent, has already been approved for nine indications.

11.03.2026

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Leerink Global Healthcare Conference 2026 Transcript

11.03.2026

Regeneron: Fairly Valued Now After A Stellar Upswing

Regeneron Pharmaceuticals, Inc. is rated a long-term Buy, but I expect near-term sideways trading due to limited new catalysts. Declining Eylea/Eylea HD revenues are largely offset by strong Dupixent growth, with Dupixent likely to exceed 50% of total revenue by 2027. Libtayo and pipeline assets show promise, but meaningful revenue impact is expected only after 2026; diversification into new areas brings both opportunity and capital allocation risk.

Regeneron Pharmaceuticals, Inc. (REGN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Regeneron Pharmaceuticals, Inc. (REGN)

Is Regeneron a Multimillionaire-Maker Stock?

REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Press Release: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Leerink Global Healthcare Conference 2026 Transcript

Regeneron: Fairly Valued Now After A Stellar Upswing

Is Regeneron a Multimillionaire-Maker Stock?

REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Press Release: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Leerink Global Healthcare Conference 2026 Transcript

Regeneron: Fairly Valued Now After A Stellar Upswing

Videos

Press releases

Press Release: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Regeneron Science Talent Search 2026 Recognizes America's Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment

Regeneron Science Talent Search 2026 Recognizes America's Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment